Unknown

Dataset Information

0

EZH2 oncogenic activity in castration-resistant prostate cancer cells is Polycomb-independent.

ABSTRACT: Epigenetic regulators represent a promising new class of therapeutic targets for cancer. Enhancer of zeste homolog 2 (EZH2), a subunit of Polycomb repressive complex 2 (PRC2), silences gene expression via its histone methyltransferase activity. We found that the oncogenic function of EZH2 in cells of castration-resistant prostate cancer is independent of its role as a transcriptional repressor. Instead, it involves the ability of EZH2 to act as a coactivator for critical transcription factors including the androgen receptor. This functional switch is dependent on phosphorylation of EZH2 and requires an intact methyltransferase domain. Hence, targeting the non-PRC2 function of EZH2 may have therapeutic efficacy for treating metastatic, hormone-refractory prostate cancer.

SUBMITTER: Xu K 

PROVIDER: S-EPMC3625962 | biostudies-literature | 2012 Dec

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Epigenetic regulators represent a promising new class of therapeutic targets for cancer. Enhancer of zeste homolog 2 (EZH2), a subunit of Polycomb repressive complex 2 (PRC2), silences gene expression via its histone methyltransferase activity. We found that the oncogenic function of EZH2 in cells of castration-resistant prostate cancer is independent of its role as a transcriptional repressor. Instead, it involves the ability of EZH2 to act as a coactivator for critical transcription factors in  ...[more]

Similar Datasets

Unknown LncRNA MALAT1 enhances oncogenic activities of EZH2 in castration-resistant prostate cancer.
| S-EPMC4747388 | biostudies-literature
Unknown PRKAR2B plays an oncogenic role in the castration-resistant prostate cancer.
| S-EPMC5351617 | biostudies-literature
Unknown Polycomb-Mediated Disruption of an Androgen Receptor Feedback Loop Drives Castration-Resistant Prostate Cancer.
| S-EPMC5243151 | biostudies-literature
Unknown Nonmetastatic castration-resistant prostate cancer.
| S-EPMC3956942 | biostudies-other
Unknown Targeting Cancer Stem Cells in Castration-Resistant Prostate Cancer.
| S-EPMC4738061 | biostudies-literature
Unknown Osteoclasts directly influence castration-resistant prostate cancer cells.
| S-EPMC9474581 | biostudies-literature
Unknown Ilicicolin A Exerts Antitumor Effect in Castration-Resistant Prostate Cancer Via Suppressing EZH2 Signaling Pathway.
| S-EPMC8578973 | biostudies-literature
Unknown Identification of castration-dependent and -independent driver genes and pathways in castration-resistant prostate cancer (CRPC).
| S-EPMC9580185 | biostudies-literature
Unknown LSD1 Inhibition Disrupts Super-Enhancer-Driven Oncogenic Transcriptional Programs in Castration-Resistant Prostate Cancer.
| S-EPMC10192194 | biostudies-literature
Unknown EZH2-induced lysine K362 methylation enhances TMPRSS2-ERG oncogenic activity in prostate cancer.
| S-EPMC8260656 | biostudies-literature